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Colorectal cancer is one of the major causes of death
worldwide. In Canada, colon cancer is the third most
commonly diagnosed cancer. [1] Fortunately, 90% of deaths
and cases of colon cancer are preventable. If detected at an
early stage, it can be cured. There are different challenges in
developing drugs for cancer treatments, these include tumor
selectivity, target specificity, drug efficacy and multidrug
resistance (MDR).
Enzymes such as methionine aminopeptidases (MetAPs) play
a major role in being a anticancer drug target. MetAP2 has
been found highly expressed in several tumours. Continuous
efforts have been made to develop structurally divergent new
MetAP2 inhibitors to enhance drug specificity and to treat
drug resistant colon cancers. NC 2213, a drug design strategy
by Pati et al. [4] to undertake structural modification of
curcumin to produce novel synthetic analogs (enones were
designed as thiol alkylators) with MetAP2 inhibitory
properties as anticancer agents.
The purpose of the present study is to identify and
investigate promising curcumin analogs displaying both
MetAP2 inhibitory and cytotoxic properties for further
development as potent anticancer drug candidates.
Abstract ConclusionResults
The compound NC 1773 has shown excellent results in docking and
Western blot analysis. The western blot indicated that protein
expression was reduced for NC 1773 against HT29 cell line.
Dunnett’s post hoc test showed significance at p<0.05 for the
treatment protocol of NC 1773 in comparison to control (cells with
absence of treatment). It has an ideal IC50 profile and predicted
bioavailability which warrants further investigation for the
mechanism of action.
❑ A library of 130 compounds were docked against MetAP2 enzyme and top 10 compounds that showed good
results for their physicochemical properties assessment were taken for cytotoxic evaluation.
❑ Among the 10 compounds, 2 compounds (NC 1768 and NC 1773) had good IC50 and GI50 profiles.
❑ NC 1773 and NC 1768 on western blot indicated that protein expression was significantly reduced for NC 1773 at
IC50 concentration against HT-29.
❑ The reduced protein expression on western blot is indicative of NC 1773 potential for inhibiting the MetAP2
enzyme in multidrug resistant HT-29 colon cancer cell line.
❑ The statistical analysis performed using Student’s t-test for paired data was not significant with p>0.05 in all 3
bivariate linear models.
❑ Dunnett’s post hoc test showed significance at p<0.05 for the treatment protocol of NC 1773 in comparison with
control (cells with absence of treatment).
1) Literature survey for identifying potent curcumin analogs
2) Creation of a database of potent cytotoxic curcumin analogs: 
comprised of 130 compounds
3) MetAP2-ligand docking studies using the database of curcumin 
analogs: Compounds with docking scores of -8.5 and below 
were taken for further evaluation.
4) Pharmacokinetic and drug-likeness studies
5) The biological properties of these compounds was evaluated by 
▪ Cytotoxic evaluation of compounds
▪ Western Blot analysis
6) Statistical analysis performed by Student’s t-test for paired
data and Dunett’s Post-Hoc test.
Methods
